Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.63 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18629293 | 0.89 | GRIN2B (0.67) | GRIN2B | |
| SCHEMBL20858825 | 0.86 | CCR3 (0.52) | GRIN2BCCR3 | |
| SCHEMBL23805631 | 0.83 | GRIN2B (0.59) | GRIN2B | |
| SCHEMBL24866256 | 0.82 | GRIN2B (0.62) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL24866251 | 0.81 | GRIN2B (0.60) | GRIN2B | |
| SCHEMBL7407241 | 0.80 | CCR3 (0.82) | GRIN2BCCR3GRIN2DGRIN3BADRA1D | |
| SCHEMBL7523207 | 0.80 | SLC6A3 (0.57) | CCR3 | |
| SCHEMBL23805618 | 0.80 | GRIN2B (0.62) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL23805595 | 0.80 | GRIN2B (0.62) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL23805564 | 0.80 | GRIN2B (0.62) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885CCR3 3425/4885GRIN2D 9/4885 |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885CCR3 3425/4885GRIN2D 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.